Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1730637 10.3389/fphar.2025.1730637 Correction Correction: Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single–center retrospective cohort study Liu et al. 10.3389/fphar.2025.1730637 Liu Ying 1 † Data curation Conceptualization Investigation Methodology Visualization Resources Writing – original draft Writing – review & editing Lin Taoyan 1 2 † Project administration Writing – review & editing Supervision Funding acquisition Conceptualization Writing – original draft Methodology Zhao Boxin 1 2 Investigation Data curation Supervision Writing – review & editing Li Yilei 1 2 * Resources Project administration Supervision Writing – review & editing Zheng Ping 1 2 * Project administration Funding acquisition Supervision Writing – review & editing Resources Department Pharmacy, Institute Nanfang Hospital, Organization Southern Medical University, Guangzhou, China Department Clinical Pharmacy Center, Institute Nanfang Hospital, Organization Southern Medical University, Guangzhou, China Correspondence: Ping Zheng, zpm321@126.com; Yilei Li, liyilei1975@163.com

These authors have contributed equally to this work and share first authorship

 14 11 2025 2025 16 1730637 23 10 2025 28 10 2025 Copyright © 2025 Liu, Lin, Zhao, Li and Zheng. 2025 Liu, Lin, Zhao, Li and Zheng https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. A Correction on Correlation analysis between plasma concentration of nilotinib and clinical efficacy and safety in patients with chronic myeloid leukemia: a single–center retrospective cohort study by Liu Y, Lin T, Zhao B, Li Y and Zheng P (2025). Front. Pharmacol. 16:1676800. doi: 10.3389/fphar.2025.1676800 nilotinib chronic myeloid leukemia plasma concentration TDM efficacy safety section-in-acceptance Pharmacology of Anti-Cancer Drugs

The funding statement was erroneously written as “This study is supported by the GuangDong Pharmaceutical Association (Nos. 2023JZ04, 2024A02036, 2025HJB01006, 2025A02036) to YL.” This has now been corrected to the following: “This study is supported by the GuangDong Pharmaceutical Association (No. 2024A02036 and 2025HJB01006 to YTL; No. 2023JZ04 and 2025A02036 to PZ).”

The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland